Clinical Trial Update: Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) [Phase 2]

View source ↗

Summary

A phase 2 trial is evaluating adding the IDH2 inhibitor enasidenib to cedazuridine-decitabine therapy for higher-risk myelodysplastic syndrome with IDH2 mutatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Cedazuridine-Decitabine (cedazuridine-decitabine)
• Enasidenib (enasidenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: RECRUITING